PTP-001 not checked

Bioventus LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.”In the company’s words, NCT05100225 on ClinicalTrials.gov
Tested for
Osteoarthritis, Knee
Main trialPhase 2
“Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).”In the company’s words, NCT05100225 on ClinicalTrials.gov

Other drugs for Osteoarthritis, Knee

All 34 drugs for Osteoarthritis, Knee

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 31 Oct 2022 Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis
Phase 1Unknown Sep 2022 Safety Study of PTP-001 for Treating Knee Osteoarthritis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow PTP-001

Following is part of Solo: you see every change to PTP-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in